Pathomics-based prediction of thymic epithelial tumor subtypes within the French RYTHMIC network.
Abstract
8112 Background: Thymic epithelial tumors (TETs) are classified into primary subtypes (A, AB, B1, B2, B3, C) and mixed classes, determined by varying proportions of tumoral and non-tumoral components, and different subtypes have different prognosis. This heterogeneity, combined with their rarity, poses significant diagnostic challenges that impact tumor treatment. We aim to develop and test a multiple-instance learning (MIL) model capable of classifying TETs major histological subtypes from hematoxylin-eosin/hematoxylin-eosin-saffron (HE/HES)-stained slides. Methods: Cases who underwent central revision by a panel of expert pathologist between 2012 and 2016 in the context of the French national RYTHMIC network were retrospectively collected, and their HE/HES slides were digitized in whole slide images (WSIs), forming the training cohort. A MIL model was trained exclusively on digitized WSIs, without clinical features, and internally validated using 3-repeated 2-fold cross-validation for the classification of major TET subtypes: A, AB, B1, B2, B3, C. Prospectively digitized WSIs from the RYTHMIC network (2022–2024) served as the testing cohort. Class predictions were assessed using AUC scores and ROC curves. Interpretability was explored through Shapley values and heatmaps. Results: A total of 456 WSIs from unique histological samples formed the training cohort, with 243 (53%) samples obtained via thymectomy. The most represented subtype was AB (n=129, 28%), followed by B2 (n=110, 24%). Internal validation achieved a mean AUC of 0.94 [sd 0.005] for histological subtypes classification. High-attention regions identified on the slides featured varying proportions of epithelial cells and lymphocytes, consistent with the biological characteristics of each subtype. The test set comprised 75 WSIs from unique histological samples, with 63 (84%) obtained via thymectomy. The most represented subtype was AB (n=35, 47%), followed by B2 (n=19, 25%). In the test set, the model achieved a mean AUC of 0.89 [95%CI 0.83–0.93] for histological subtypes classification. Conclusions: Our model shows promise for diagnosing TET major subtypes, emphasizing the value of digital pathology in identifying and classifying rare entities. We are currently reviewing discrepancies between MIL and pathologists' diagnoses in subtype classification within the test set to evaluate the potential of artificial intelligence in aiding the diagnosis of complex cases. The final results will be presented at the congress.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (16)
Lodovica Zullo
Medical Oncology Department, Gustave Roussy, Villejuif, France
Mathilde Bateson
Owkin France, Paris, France
Jose Carlos Benitez-Montanez
Medical Oncology Department, Virgen de la Victoria University Hospital, Malaga, Spain
Audrey Mansuet-Lupo
Damien Sizaret
Juan Florez-Arango
Clinica Las Américas – AUNA, Medellin, Colombia
Álvaro López-Gutiérrez
Daniela Miliziano
Department of Cancer Medicine, Gustave Roussy, Villejuif, France
Pascale Missy
The French Cooperative Thoracic Intergroup, Paris, France
Vincent Thomas De Montpreville
Marie Lannelongue Hospital, Le Plessis-Robinson, France
Olaf Mercier
Department of Thoracic Surgery and Heart-Lung Transplantation, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France
Jordi Remon Masip
Gustave Roussy, Paris, France
David Planchard
Nicolas Girard
Institut Curie, Institut du Thorax Curie-Montsouris, Paris
Thierry Molina
Department of Pathology, Hôpital Necker-Enfants Malades, Paris, France
Benjamin Besse